Compare Bristol-Myers Squibb Co (BMY) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Firy Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.75 (market cap $116.30B), while Firy Inc. trades at $8.4 (market cap $125.48M). The key difference: Bristol-Myers Squibb Co is far larger — about 926.8× Firy Inc.'s market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| BMY | FIRY | |
|---|---|---|
Market Cap | $116.30B | $125.48M |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $12.45 |
52-Week Low | $42.60 | $2.28 |
Enterprise Value | $152.24B | $69.16M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FIRY trades at $8.44, down 1.17% on the day, with a bullish technical signal from moving averages despite recent price weakness. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -57.48%. Recent developments include a corporate rebrand from Skillz Inc. and a major legal victory, though cash flow remains negative.
The outlook remains challenging due to persistent unprofitability and negative cash flows, offset by potential from the rebrand and legal win. Risks include high burn rate and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, suggesting cautious optimism pending sustained operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
